- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- homo-hexamer
- Ligands
- 6 x XF2: (2E)-2-[(4-chlorophenyl)methylidene]hydrazine-1-carboximidamide(Non-covalent)
- 42 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
DMS.2: 5 residues within 4Å:- Chain A: F.44, D.46, F.47, I.48
- Ligands: XF2.1
Ligand excluded by PLIPDMS.3: 3 residues within 4Å:- Chain A: E.159, R.257
- Ligands: DMS.7
Ligand excluded by PLIPDMS.4: 8 residues within 4Å:- Chain A: R.262, I.288, T.289, H.290, Q.417, T.418
- Ligands: GOL.6, PEG.12
Ligand excluded by PLIPDMS.5: 8 residues within 4Å:- Chain A: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, D.413
Ligand excluded by PLIPDMS.7: 4 residues within 4Å:- Chain A: W.309, E.421
- Ligands: DMS.3, GOL.6
Ligand excluded by PLIPDMS.8: 5 residues within 4Å:- Chain A: P.28, W.33, R.57, P.61, A.65
Ligand excluded by PLIPDMS.9: 5 residues within 4Å:- Chain A: A.367, E.368, E.370, R.396, T.397
Ligand excluded by PLIPDMS.14: 5 residues within 4Å:- Chain B: F.44, D.46, F.47, I.48
- Ligands: XF2.13
Ligand excluded by PLIPDMS.15: 3 residues within 4Å:- Chain B: E.159, R.257
- Ligands: DMS.19
Ligand excluded by PLIPDMS.16: 8 residues within 4Å:- Chain B: R.262, I.288, T.289, H.290, Q.417, T.418
- Ligands: GOL.18, PEG.24
Ligand excluded by PLIPDMS.17: 8 residues within 4Å:- Chain B: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, D.413
Ligand excluded by PLIPDMS.19: 4 residues within 4Å:- Chain B: W.309, E.421
- Ligands: DMS.15, GOL.18
Ligand excluded by PLIPDMS.20: 5 residues within 4Å:- Chain B: P.28, W.33, R.57, P.61, A.65
Ligand excluded by PLIPDMS.21: 5 residues within 4Å:- Chain B: A.367, E.368, E.370, R.396, T.397
Ligand excluded by PLIPDMS.26: 5 residues within 4Å:- Chain C: F.44, D.46, F.47, I.48
- Ligands: XF2.25
Ligand excluded by PLIPDMS.27: 3 residues within 4Å:- Chain C: E.159, R.257
- Ligands: DMS.31
Ligand excluded by PLIPDMS.28: 8 residues within 4Å:- Chain C: R.262, I.288, T.289, H.290, Q.417, T.418
- Ligands: GOL.30, PEG.36
Ligand excluded by PLIPDMS.29: 8 residues within 4Å:- Chain C: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, D.413
Ligand excluded by PLIPDMS.31: 4 residues within 4Å:- Chain C: W.309, E.421
- Ligands: DMS.27, GOL.30
Ligand excluded by PLIPDMS.32: 5 residues within 4Å:- Chain C: P.28, W.33, R.57, P.61, A.65
Ligand excluded by PLIPDMS.33: 5 residues within 4Å:- Chain C: A.367, E.368, E.370, R.396, T.397
Ligand excluded by PLIPDMS.38: 5 residues within 4Å:- Chain D: F.44, D.46, F.47, I.48
- Ligands: XF2.37
Ligand excluded by PLIPDMS.39: 3 residues within 4Å:- Chain D: E.159, R.257
- Ligands: DMS.43
Ligand excluded by PLIPDMS.40: 8 residues within 4Å:- Chain D: R.262, I.288, T.289, H.290, Q.417, T.418
- Ligands: GOL.42, PEG.48
Ligand excluded by PLIPDMS.41: 8 residues within 4Å:- Chain D: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, D.413
Ligand excluded by PLIPDMS.43: 4 residues within 4Å:- Chain D: W.309, E.421
- Ligands: DMS.39, GOL.42
Ligand excluded by PLIPDMS.44: 5 residues within 4Å:- Chain D: P.28, W.33, R.57, P.61, A.65
Ligand excluded by PLIPDMS.45: 5 residues within 4Å:- Chain D: A.367, E.368, E.370, R.396, T.397
Ligand excluded by PLIPDMS.50: 5 residues within 4Å:- Chain E: F.44, D.46, F.47, I.48
- Ligands: XF2.49
Ligand excluded by PLIPDMS.51: 3 residues within 4Å:- Chain E: E.159, R.257
- Ligands: DMS.55
Ligand excluded by PLIPDMS.52: 8 residues within 4Å:- Chain E: R.262, I.288, T.289, H.290, Q.417, T.418
- Ligands: GOL.54, PEG.60
Ligand excluded by PLIPDMS.53: 8 residues within 4Å:- Chain E: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, D.413
Ligand excluded by PLIPDMS.55: 4 residues within 4Å:- Chain E: W.309, E.421
- Ligands: DMS.51, GOL.54
Ligand excluded by PLIPDMS.56: 5 residues within 4Å:- Chain E: P.28, W.33, R.57, P.61, A.65
Ligand excluded by PLIPDMS.57: 5 residues within 4Å:- Chain E: A.367, E.368, E.370, R.396, T.397
Ligand excluded by PLIPDMS.62: 5 residues within 4Å:- Chain F: F.44, D.46, F.47, I.48
- Ligands: XF2.61
Ligand excluded by PLIPDMS.63: 3 residues within 4Å:- Chain F: E.159, R.257
- Ligands: DMS.67
Ligand excluded by PLIPDMS.64: 8 residues within 4Å:- Chain F: R.262, I.288, T.289, H.290, Q.417, T.418
- Ligands: GOL.66, PEG.72
Ligand excluded by PLIPDMS.65: 8 residues within 4Å:- Chain F: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, D.413
Ligand excluded by PLIPDMS.67: 4 residues within 4Å:- Chain F: W.309, E.421
- Ligands: DMS.63, GOL.66
Ligand excluded by PLIPDMS.68: 5 residues within 4Å:- Chain F: P.28, W.33, R.57, P.61, A.65
Ligand excluded by PLIPDMS.69: 5 residues within 4Å:- Chain F: A.367, E.368, E.370, R.396, T.397
Ligand excluded by PLIP- 18 x GOL: GLYCEROL(Non-functional Binders)
GOL.6: 8 residues within 4Å:- Chain A: L.157, I.288, T.418, A.419, F.420, E.421
- Ligands: DMS.4, DMS.7
Ligand excluded by PLIPGOL.10: 7 residues within 4Å:- Chain A: S.103, F.104, V.105, H.139, A.140, S.141, Y.146
Ligand excluded by PLIPGOL.11: 6 residues within 4Å:- Chain A: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.18: 8 residues within 4Å:- Chain B: L.157, I.288, T.418, A.419, F.420, E.421
- Ligands: DMS.16, DMS.19
Ligand excluded by PLIPGOL.22: 7 residues within 4Å:- Chain B: S.103, F.104, V.105, H.139, A.140, S.141, Y.146
Ligand excluded by PLIPGOL.23: 6 residues within 4Å:- Chain B: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.30: 8 residues within 4Å:- Chain C: L.157, I.288, T.418, A.419, F.420, E.421
- Ligands: DMS.28, DMS.31
Ligand excluded by PLIPGOL.34: 7 residues within 4Å:- Chain C: S.103, F.104, V.105, H.139, A.140, S.141, Y.146
Ligand excluded by PLIPGOL.35: 6 residues within 4Å:- Chain C: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.42: 8 residues within 4Å:- Chain D: L.157, I.288, T.418, A.419, F.420, E.421
- Ligands: DMS.40, DMS.43
Ligand excluded by PLIPGOL.46: 7 residues within 4Å:- Chain D: S.103, F.104, V.105, H.139, A.140, S.141, Y.146
Ligand excluded by PLIPGOL.47: 6 residues within 4Å:- Chain D: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.54: 8 residues within 4Å:- Chain E: L.157, I.288, T.418, A.419, F.420, E.421
- Ligands: DMS.52, DMS.55
Ligand excluded by PLIPGOL.58: 7 residues within 4Å:- Chain E: S.103, F.104, V.105, H.139, A.140, S.141, Y.146
Ligand excluded by PLIPGOL.59: 6 residues within 4Å:- Chain E: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.66: 8 residues within 4Å:- Chain F: L.157, I.288, T.418, A.419, F.420, E.421
- Ligands: DMS.64, DMS.67
Ligand excluded by PLIPGOL.70: 7 residues within 4Å:- Chain F: S.103, F.104, V.105, H.139, A.140, S.141, Y.146
Ligand excluded by PLIPGOL.71: 6 residues within 4Å:- Chain F: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIP- 6 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
PEG.12: 9 residues within 4Å:- Chain A: L.261, H.269, I.287, T.289, H.290, D.293, P.294, Q.417
- Ligands: DMS.4
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:T.289
- Water bridges: A:L.261, A:I.288
PEG.24: 9 residues within 4Å:- Chain B: L.261, H.269, I.287, T.289, H.290, D.293, P.294, Q.417
- Ligands: DMS.16
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:T.289
- Water bridges: B:L.261, B:I.288
PEG.36: 9 residues within 4Å:- Chain C: L.261, H.269, I.287, T.289, H.290, D.293, P.294, Q.417
- Ligands: DMS.28
3 PLIP interactions:3 interactions with chain C- Hydrogen bonds: C:T.289
- Water bridges: C:L.261, C:I.288
PEG.48: 9 residues within 4Å:- Chain D: L.261, H.269, I.287, T.289, H.290, D.293, P.294, Q.417
- Ligands: DMS.40
2 PLIP interactions:2 interactions with chain D- Water bridges: D:L.261, D:I.288
PEG.60: 9 residues within 4Å:- Chain E: L.261, H.269, I.287, T.289, H.290, D.293, P.294, Q.417
- Ligands: DMS.52
2 PLIP interactions:2 interactions with chain E- Water bridges: E:L.261, E:I.288
PEG.72: 9 residues within 4Å:- Chain F: L.261, H.269, I.287, T.289, H.290, D.293, P.294, Q.417
- Ligands: DMS.64
2 PLIP interactions:2 interactions with chain F- Water bridges: F:L.261, F:I.288
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pang, A.H. et al., Discovery and Mechanistic Analysis of Structurally Diverse Inhibitors of Acetyltransferase Eis among FDA-Approved Drugs. Biochemistry (2023)
- Release Date
- 2023-02-01
- Peptides
- N-acetyltransferase Eis: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
AC
AD
AE
AF
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- homo-hexamer
- Ligands
- 6 x XF2: (2E)-2-[(4-chlorophenyl)methylidene]hydrazine-1-carboximidamide(Non-covalent)
- 42 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
- 18 x GOL: GLYCEROL(Non-functional Binders)
- 6 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pang, A.H. et al., Discovery and Mechanistic Analysis of Structurally Diverse Inhibitors of Acetyltransferase Eis among FDA-Approved Drugs. Biochemistry (2023)
- Release Date
- 2023-02-01
- Peptides
- N-acetyltransferase Eis: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
AC
AD
AE
AF
A